Dóchas Life Sciences’ Post

Iron Deficiency Is Prevalent in Patients With Non-Anemia, Non-Dialysis-Dependent-CKD: The authors note that transferrin saturation levels may be a modifiable risk factor of chronic kidney disease (CKD) progression and all-cause mortality. #finance #pharmacy #lifesciences

Exciting advancements in lipid management for individuals with diabetes! New therapies like PCSK9 inhibitors and inclisiran show promise in reducing LDL-C and CV risk without increasing diabetes risk. Check out this article for more details.  #Diabetes #CardiovascularHealth #LipidManagement #HeartHealth #LDLCholesterol #CardiovascularHealth #DiabetesRisk https://lnkd.in/eH3m3uCq

Reducing proteinuria forms the cornerstone of chronic kidney disease management. The last decade has seen the addition of many protein-reducing medicines, each with its unique set of traits. Along comes the Finerenone, a protein-reducing medicine with an even more brilliant set of features. Finerenone is now an FDA-approved drug for proteinuria treatment in diabetic kidney disease alone. However, this kidney-protective drug can potentially treat chronic kidney disease of any origin, a point still awaiting validation with research. To understand how Finereone does its magic, read the blog post 👇 https://lnkd.in/g8cgJbtX #kidneydisease #ckd #proteinuriatreatment #finerenone #diabetes #diabetickidneydisease

Helloo connections!! I'm here to share an article about Chronic Kidney Disease. Defined as a persistent abnormality in kidney structure or function (eg, glomerular filtration rate [GFR] <60 mL/min/1.73 m2 or albuminuria ≥30 mg per 24 hours) for more than 3 months, CKD affects 8% to 16% of the population worldwide. In developed countries, CKD is most commonly attributed to diabetes and hypertension. However, less than 5% of patients with early CKD report awareness of their disease. Among individuals diagnosed as having CKD, staging and new risk assessment tools that incorporate GFR and albuminuria can help guide treatment, monitoring, and referral strategies. Optimal management of CKD includes cardiovascular risk reduction (eg, statins and blood pressure management), treatment of albuminuria (eg, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers), avoidance of potential nephrotoxins (eg, nonsteroidal anti-inflammatory drugs), and adjustments to drug dosing (eg, many antibiotics and oral hypoglycemic agents). Patients also require monitoring for complications of CKD, such as hyperkalemia, metabolic acidosis, hyperphosphatemia, vitamin D deficiency, secondary hyperparathyroidism, and anemia. Those at high risk of CKD progression (eg, estimated GFR <30 mL/min/1.73 m2, albuminuria ≥300 mg per 24 hours, or rapid decline in estimated GFR) should be promptly referred to a nephrologist. #snsinstitutions #snsdesignthinkers #designthinking

VITAMIN D - why are Governments and mainstream medics ignoring this multi-tasking, immunomodulating, pre-hormone? Because it cannot be Patented - simple! I commend this excellent review study and meta-analysis (see link below) to LinkedIn Members for your consideration.  Take Home: “COVID-19 mortality risk correlates inversely with vitamin D3 status, and a mortality rate close to zero could theoretically be achieved at 50 ng/ml 25(OH)D3” There are several additional important functions of vitamin D3 supporting immune defense [18,75,87,88]: Vitamin D decreases the production of Th1 cells. Thus, it can suppress the progression of inflammation by reducing the generation of inflammatory cytokines [72,89,90]. Vitamin D3 reduces the severity of cytokine release syndrome (CRS). This “cytokine storm” causes multiple organ damage and is therefore the main cause of death in the late stage of SARS- CoV-2 infection. The systemic inflammatory response due to viral infection is attenuated by promoting the differentiation of regulatory T cells [91–94]. Vitamin D3 induces the production of the endogenous antimicrobial peptide cathelicidin (LL-37) in macrophages and lung epithelial cells, which acts against invading respiratory viruses by disrupting viral envelopes and altering the viability of host target cells [51,95–100]. Experimental studies have shown that vitamin D and its metabolites modulate endothelial function and vascular permeability via multiple genomic and extragenomic pathways [101,102]. Vitamin D reduces coagulation abnormalities in critically ill COVID-19 patients [103–105]. Link to study: https://lnkd.in/eSx_46g3

Babakr A. et. al . Investigation of Hyperlipidemia Associated with Increased Levels of Oxidized Low-Density Lipoproteins and 8-Hydroxy-2´-Deoxyguanosine. Diabetes Metab Syndr Obes. 2023 Feb 14;16:447-455. ''The aim of the present study was to evaluate the association between lipid status and the levels of oxidized low-density lipoproteins and 8-hydroxy-2´-deoxyguanosine. Oxidized low-density lipoproteins and 8-hydroxy-2´-deoxyguanosine were then compared in normal and high lipid profile groups. The obtained results were then statistically analyzed.8-Hydroxy-2´-deoxyguanosine was found to be positively correlated with hypercholesterolemia, hypertriglyceridemia, and high levels of low-density lipoproteins , respectively . A positive correlation was observed also between the levels of oxidized low-density lipoproteins and the same lipid profile parameters, respectively .The present study suggests that disturbance in lipid profile may result in increased levels of oxidized low-density lipoproteins and oxidative stress in the study group; however, a larger sample is needed to confirm the present findings''. https://lnkd.in/dACCzFhx

New #Articles in #Diabetes and #Metabolic Syndrome: #Clinical #Research/#Reviews (#IMPACTFACTOR, 10, Ranked #1 3Journal for Diabetes/Endo in #Asia.) Response to lowering plasma #glucose is characterised by decreased #oxyntomodulin: Results from a #randomised #controlled #trial https://lnkd.in/ge2m6ym5

The way we look at healthcare has dramatically evolved in the last 50 years. In today’s world is not just about access to medical care, but rather about learning how to remain “healthy” based on our “exposure” to the environment. In this context, the food we eat is becoming an increasingly important factor in disease prevention. For example, in the United States over 80% of the population suffers some degree of insulin resistance due to poor food choices. The food industry has adapted by introducing many “healthy” options. An interesting experiment has been the introduction of natural sugar alternatives such as Erythritol, Mannitol, Sorbitol, Xylitol, and Maltitol. Despite digestive side effects, these additives are well tolerated. However, this is a complex topic. Earlier in 2024, a clinical research group found Xylitol associated with risk of cardiovascular disease (https://lnkd.in/gbnsqyPQ). The central question here is: what else is wrong in our efforts to make it better? Regardless of the answer, what we eat will continue to be a personal decision with an outcome in quality of life and longevity.

Pharmacists Have a Significant Role in Chronic Kidney Disease: The Kidney Disease: Improving Global Outcomes guidelines can provide pharmacists with approaches to minimizing chronic kidney disease progression and complications. #finance #pharmacy #lifesciences

📛 THE DARK SIDE OF METFORMIN Metformin, a drug used to manage type 2 diabetes, has recently gained a lot of attention for its potential longevity-promoting effects. But metformin can also have detrimental effects on gut health. 🔬 Low levels of oxygen in the gut, or epithelial hypoxia, help support healthy gut microbial homeostasis by preventing the expansion of oxygen-hungry pathogens like Proteobacteria. The PPAR-γ signaling pathway activates mitochondrial oxygen consumption in the mucosal surface of the colon to maintain this state of physiological hypoxia. ➡ Mesalazine, a drug often prescribed to treat IBD, activates the PPAR-γ signaling pathway in the colonic epithelium while metformin and berberine block it, inducing dysbiosis. 📍REFERENCE: Yael Litvak, Andreas J. Bäumler. "Microbiota-Nourishing Immunity: A Guide to Understanding Our Microbial Self." Immunity, Volume 51, Issue 2 (2019), 214-224. doi: 10.1016/j.immuni.2019.08.003.